Construction of an Expression Vector Containing a Novel Fusion Sequence from Middle Region of NS3 and Truncated Core Genes of Hepatitis C Virus

Authors

  • F Sabahi Department of Virology, Tarbiat Modares University, Tehran, Iran
  • M Ravanshad Department of Virology, Tarbiat Modares University, Tehran, Iran
  • M Saberi-Firoozi GastroenteroHepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • MH Modarressi Department of Medical Genetic, Tehran University of Medical Sciences, Tehran, IranDepartment of Medical Genetic, Tehran University of Medical Sciences, Tehran, Iran
  • SM Moazzeni Department of Immunology, Tarbiat Modares University, Tehran, Iran
  • SY Hosseini Department of Virology, Tarbiat Modares University, Tehran, Iran
Abstract:

Background and Aims: DNA constructs containing HCV antigens have become one of the vaccine candidates for induction of anti-HCV cellular and humoral immunity. In this study, we constructed a novel expressing vector harboring a fusion sequence derived from an overlapping fragment in the middle of NS3 and a truncated core fragment to avoid troubles reported to be associated with full gene expression. Methods: The partial NS3 (pNS3) and core genes were amplified by RT-PCR method using serum of HCV infected patient harboring genotype 1a of virus. After purification and cloning the genes into TA-cloning vector, they were evaluated by sequencing and restriction digestion analysis. The resultant pNS3 and core gene subcloned into expression vector separately followed by expression evaluation using RT-PCR and western blotting. The core expressing vector exploited for amplification of a new truncated core (50-160aa) sequence using PCR. Truncated core fragment was first cloned into TA vector at a natural restriction site downstream of pNS3 fragment. The resulting fused sequence was cut and subcloned into expression vector. The integrity and ability of expression of this fused sequence was evaluated by sequencing followed by RT-PCR analysis after DNA transfection into 293 cells. Results: The repeated sequencing data showed sequence integrity among the gene fragments as well as homology among them and reference 1a sequences. The colony-PCR, RT-PCR and western blotting confirmed insertion of genes into expressing vector, expression of genes in 293 cell line and production of protein in 293 respectively. Conclusion: This new expressing vector harboring a novel fused fragments of NS3 and core genes may overcome shortcomings in vaccine design in the setting of HCV disease.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

construction of an expression vector containing a novel fusion sequence from middle region of ns3 and truncated core genes of hepatitis c virus

background and aims: dna constructs containing hcv antigens have become one of the vaccine candidates for induction of anti-hcv cellular and humoral immunity. in this study, we constructed a novel expressing vector harboring a fusion sequence derived from an overlapping fragment in the middle of ns3 and a truncated core fragment to avoid troubles reported to be associated with full gene express...

full text

construction and preparation of three recombinant adenoviruses expressing truncated ns3 and core genes of hepatitis c virus for vaccine purposes

background in spite of dozens of clinical trials to establish effective therapeutic and/or preventive vaccine to resolve hcv infection, no real vaccine has been proved to date. genetic vaccines based on replication-defective adenoviruses have proved to elicit strong and long lasting t-cell responses against a number of viral antigens and are even currently being used for vaccine trials in human...

full text

cloning and evaluation of expression of a novel overlapping region of ns3 gene of hepatitis c virus by expressing vector

objective: in this project, our aim was to construct a novel expressing vector harboring a new sequence from overlapping region of ns3 gene of hcv from infected iranian patient. materials and methods: the partial ns3 (pns3) gene was amplified by nested-rt-pcr method using sera of hcv infected patients harboring genotype 1a. after purification and cloning the pns3 into ta-cloning vector, the be...

full text

Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate

Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic and anaphylactic vaccines design has not been fast enough. This study was aimed to prepare and assess a recombinant fusion protein core-NS3 (rC-N) ...

full text

Construction and Preparation of Three Recombinant Adenoviruses Expressing Truncated NS3 and Core Genes of Hepatitis C Virus for Vaccine Purposes

BACKGROUND In spite of dozens of clinical trials to establish effective therapeutic and/or preventive vaccine to resolve HCV infection, no real vaccine has been proved to date. Genetic vaccines based on replication-defective adenoviruses have proved to elicit strong and long lasting T-cell responses against a number of viral antigens and are even currently being used for vaccine trials in human...

full text

Construction of pIRES2 vector encoding truncated NS3 of HCV and IL-18 for DNA vaccine studies

Introduction: Long term complications of hepatitis C virus (HCV) infection include fibrosis, cirrhosis, and hepatocellular carcinoma and although the disease is treatable with the newly introduced direct acting antivirals, but factors such as drug resistance, viral genotype and adverse effects can limit the effectiveness of therapy. Therefore, development of effective, safe and affordable proph...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue None

pages  17- 27

publication date 2010-10

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023